Why choose Invokana (canagliflozin) - After first line, take a firm line
Invokana Patient Selection Icon

Patient Selection

Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as adjunct to diet and exercise

  • Both improvements in glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of T2DM. 1
Invokana can be used: 1
As monotherapy
In combination with other diabetes drugs
  • Sulphonylureas
  • Thiazolidinones
  • DPP 4 inhibitors
  • GLP-1 receptor agonists
  • Insulin
In older patients without the need for dose reduction
  • Safety profile in patients ≥65 years is generally consistent with younger patients
  • Use with caution in patients ≥75 years, taking account of renal function and risk of volume depletion
In patients with mild to moderate renal impairment
  • In patients with eGFR of 60-90ml/min/1.73m2
  • Should not be initiated in patients with an eGFR<60ml/min/1.73m2
  • Should not be used in patients with an eGFR<45ml/min/1.73m2
  • In patients tolerating Invokana with eGFR persistently below 60ml/min/1.73m2 the dose should be adjusted to or maintained at 100mg/day
In patients with hepatic impairment
  • In mild to moderate hepatic impairment without the need for dose adjustment
  • Not recommended for patients with severe hepatic impairment
References
  1. Reference 1(7)